5alpha,6alpha-epoxy-17alpha-picolyl-androstane-n-oxide-3beta,17beta-diol

5alpha,6alpha-epoxy-17alpha-picolyl-androstane-n-oxide-3beta,17beta-diol is a synthetic heterocyclic steroid derivative investigated for its potential as an anticancer agent, particularly against triple-negative breast cancer (TNBC). It is an N-oxide derivative of a 17-picolyl androstane, featuring an epoxide group at the 5,6-position of the steroid nucleus. Preclinical research demonstrates that the compound exerts strong antiproliferative effects on MDA-MB-231 cells by inducing apoptosis and causing significant changes in cell cycle distribution. This compound is part of a broader effort to develop targeted steroidal therapies for aggressive cancer subtypes that lack traditional receptors like ER, PR, and HER2. Developed by researchers at the University of Novi Sad, it represents a novel approach in steroidal anticancer drug discovery.

Other names

5alpha,6alpha-epoxy-17alpha-(2-picolyl)androstane-3beta,17beta-diol N-oxide5α,6α-epoxy-17α-picolyl-androstane-N-oxide-3β,17β-diol